YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCI...(-------------------- YM BIOSCIENCES I...)

Date:5/14/2009

-------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Deficit (Expressed in Canadian dollars) ------------------------------------------------------------------------- Three months ended Nine months ended March 31, March 31, 2009 2008 2009 2008 ------------------------------------------------------------------------- (Unaudited) (Unaudited) Deficit, beginning of period $(139,513,082) $(126,400,938) $(133,182,485) $(118,296,741) Loss for the period (3,474,839) (3,818,647) (9,805,436) (11,922,844) ------------------------------------------------------------------------- Deficit, end of period $(142,987,921) $(130,219,585) $(142,987,921) $(130,219,585) ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Cash Flows (Expressed in Canadian dollars) ------------------------------------------------------------------------- Three months ended Nine months ended March 31, March 31, 2009 2008 2009 2008 ------------------------------------------------------------------------- (Unaudited) (Unaudited) Cash provided by (used in): Operating activities: Loss for the period $ (3,474,839) $ (3,818,647) $ (9,805,436) $ (11,922,844) Items not involving cash: Amortiza- tion of property and
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
2. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
3. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
4. Neurocrine Biosciences Reports First Quarter 2009 Results
5. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
8. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
9. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Cell Biosciences Launches Next-Generation Protein Characterization System